Once-daily aminoglycoside dosing: An update on current literature

American Journal of Health-System Pharmacy

Volumn 72, Issue 16, 2015, Pages 1357-1364

  Stankowicz, Matthew S ^a   Ibrahim, Jad ^a   Brown, Daniel L ^a  

^a PALM BEACH ATLANTIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; GENTAMICIN; NETILMICIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; APPENDICITIS; ARTICLE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GRAM NEGATIVE SEPSIS; HUMAN; INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; DRUG ADMINISTRATION; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; TREATMENT OUTCOME;

EID: 84957697889     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp140564     Document Type: Article

References (52)

1. Mithani H, Brown G. The economic impact of once-daily versus conventional administration of gentamicin and tobramycin. Pharmacoeconomics. 1996; 10:494-503.
2. Streetman DS, Nafziger AN, Destache CJ, Bertino JS. Individualized pharmacokinetic monitoring results in less amino- glycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001;21:443-51.
3. Prins JM, Buller HR, Kuijper EJ et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993 341:335-9.
4. Chuck SK, Raber SR, Rodvold KA, Areff D. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis. 2000; 30:433-9.
5. Prescott WA Jr. A survey of extended- interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Respir Care. 2014; 59:1353-9.
6. Fisman DN, Kaye KM. Once-daily dosing of aminoglycoside antibiotics. Infect Dis Clin North Am. 2000; 14:475-87.
7. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987; 155:93-9.
8. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother. 1985; 15(suppl A):37-46.
9. Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ. Postantibiotic effect in Pseu- domonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother. 1994; 33:937-47.
10. Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy. 1999; 19:1252-60.
11. Begg EJ, Murray L, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995; 39:605-9.
12. Barclay ML, Begg EJ, Duffull SB, Buttimore RC. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Aust NZ J Med. 1995;25:230-5.
13. Rybak MJ, Abate BJ, Kang SL et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999; 43:1549-55.
14. Sanchez-Alcaraz A, Vargas A, Quintana MB et al. Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. J. Clin Pharm Titer. 1998; 23:367-73.
15. Sturm AW. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989; 159:931-7.
16. Hollender LF, Bahnini J, de Manzini N et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother. 1989; 23:773-83.
17. Prins JM, Koopmans RP, Buller HR et al. Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Eur J Clin Pharmacol. 1995; 14:531-5.
18. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacokinetics of tobramycin in adults with cystic fibrosis: Implications for once-daily administration. Antimicrob Agents Chemother. 2000; 44:809-13.
19. Rodman DP, Maxwell A J, McKnight JT. Extended dosage intervals for aminoglycosides. Am JHospPharm. 1994; 51:2016- 21.
20. Bates RD, Nahata MC. Once-daily administration of aminoglycosides. Ann Pharmacother. 1994; 28:757-66.
21. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J. Antimicrob Chemother. 1997; 39:677-86.
22. Smyth A, Tan KH, Hyman-Taylor P et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: A randomised controlled trial. Lancet. 2005; 365:573-8.
23. Bailey TC, Little JR, Littenberg B et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:786-95.
24. Begg EJ, Peddie BA, Chambers ST, Boswell DR. Comparison of gentamicin dosing regimens using an in-vitro model. J Antimicrob Chemother. 1992; 29:427-33.
25. Nicolau DP, Freeman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. J Antimicrob Chemother. 1995; 39:650-5.
26. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997; 24:796-809.
27. Galloe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J. Clin Pharmacol. 1995;48:39-43.
28. Prescott WA Jr, Nagel JL. Extended- interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy. 2010; 30:95-108.
29. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: A meta-analysis. Br J Med. 1996;312:338-45.
30. Verpooten GA, Giuliano RA, Verbist L et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989; 45:22-7.
31. Prins JM, Weverling GJ, de Blok K et al. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother. 1996; 40:2494-9.
32. Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy: Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet. 1999; 36:89-98.
33. Bertino JS, Booker LA, Franck PA et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1997; 167:173-9.
34. Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989; 24:281-93.
35. De Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin Pharmacokinet. 1987; 13:228-53.
36. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacokinetics of tobramycin in adults with cystic fibrosis: Implications for once-daily administration. Antimicrob Agents Chemother. 2000; 44:809-13.
37. Smyth A, Tan KH, Hyman-Taylor P et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: A randomised controlled trial. Lancet. 2005; 365:573-8.
38. Whitehead A, Conway SP, Etherington C et al. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J. 2002; 19:303-9.
39. Stabler SN, Ensom MH. Extended- interval aminoglycoside therapy for adults with febrile neutropenia: A systematic review. Can J Hosp Pharm. 2011; 64:182-91.
40. Rozdzinski F., Kern WV, Reichle A et al. Once-daily versus thrice-daily dosing of netilmicin in combination with beta- lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother. 1993; 31:585-98.
41. Peterson AK, Duffull SB. Population analysis of once-daily dosing of gentamicin in patients with neutropenia. Aust NZ J Med. 1990;28:311-5.
42. Hoey LL, Tschida SJ, Rotschafer JC et al. Wide variation in single, daily dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil. 1997; 18:116-24.
43. Rea RS, Capitano B, Bies R et al. Subopti- mal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008; 30:674-81.
44. Barletta JF, Johnson SB, Nix DE et al. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma. 2000; 49:869-72.
45. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.
46. Anaizi N. Once-daily dosing of aminoglycosides: A consensus document, Int J Clin Pharmacol Ther. 1997; 35:223-6.
47. Aminoglycosides, overview [monograph]. In: Sanford Antimicrobial Guide [online database). Sperryville, VA: Sanford Guide (accessed 2014 Jul 1).
48. Wallace AW, Jones M, Bertino JS. Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy. 2002;22:1077-83.
49. Demczar DJ, Nafziger AN, Bertino JS. Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once-daily aminoglycoside dosing. Anti- microb Agents Chemother. 1997; 41:1115- 9.
50. Thomson AH, Duncan N, Silverstein B et al. Development of guidelines for gentamicin dosing. I Antimicrob Chemother. 1996; 38:885-93.
51. Nicolau DP, Wu AH, Fitiocchiaro S et al. Once-daily aminoglycoside dosing: Impact on requests and costs for therapeutic drug monitoring. Ther Drug Monit. 1996; 18:263-6.
52. Hitt CM, Klepser ME, Nightingale CH et al. Pharmacoeconomic impact of once- daily aminoglycoside administration. Pharmacotherapy. 1997; 17:810-4.